Clinical value of individualized pharmaceutical services for patients receiving vancomycin for severe infections: a retrospective case-control study based on real-world data.
10.12122/j.issn.1673-4254.2020.10.02
- Author:
Haiqin CHEN
1
;
Qingping SHI
1
;
Lingti KONG
1
;
Ran SANG
1
;
Meiling YU
1
;
Jun SUN
1
;
Yulin ZHU
1
;
Jinxiu ZHU
1
Author Information
1. Department of Pharmacy, First Affiliated Hospital, Bengbu Medical College, Bengbu 233000, China.
- Publication Type:Journal Article
- Keywords:
clinical value;
cost-effectiveness analysis;
propensity score matching;
vancomycin
- MeSH:
Anti-Bacterial Agents/therapeutic use*;
Humans;
Infections/drug therapy*;
Pharmaceutical Services;
Retrospective Studies;
Vancomycin/therapeutic use*
- From:
Journal of Southern Medical University
2020;40(10):1380-1389
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To assess the clinical value of individualized pharmaceutical services for patients receiving vancomycin for severe infections and establish clinical monitoring procedures during vancomycin treatment.
METHODS:Data were collected from patients with severe infections who received vancomycin treatment with individualized pharmacy services (test group, 144 cases) or without such services (control group, 884 cases) between January, 2017 and December, 2018. Using propensity score matching, the patients in the two groups with comparable baseline data were selected for inclusion in the study (62 in each group), and the efficacy, safety and economic indicators were compared between the two groups.
RESULTS:The curative effects of the treatment did not differ significantly between the two groups, with the overall response rates of 95.16% in the test group and 91.94% in the control group (
CONCLUSIONS:The participation of clinical pharmacists during the treatment can improve the clinical benefits of vancomycin in patients with severe infections.
